Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Recurrences of ovarian cancer can be detected earlier and more accurately with PET/CT

Due to the lack of studies, there is currently no proof that patients with ovarian cancer can benefit from positron emission tomography (PET) alone or in combination with computed tomography (CT). As regards diagnostic accuracy, in certain cases, recurrences can be detected earlier and more accurately with PET or PET/CT than with conventional imaging techniques.

9 Aug 2012

Inaugural event of National Women's Survivors Convention to be held in Nashville

In August 2013, Nashville will be the host city to the National Women's Survivors Convention (NWSC), a first of its kind national event designed to celebrate women cancer survivors.

9 Aug 2012

Clovis Oncology reports net loss of $15.7 million for second quarter 2012

Clovis Oncology, Inc. today reported financial results for the second quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.

8 Aug 2012

Donations for TGen ovarian cancer research will be matched up to $100,000 by philanthropists

Through Sept. 30, donations for ovarian cancer research at the Translational Genomics Research Institute (TGen) will be matched - up to $100,000 - by philanthropists Lynn and Foster Friess.

8 Aug 2012

New class of drugs reduces adverse effects of cellular damage from cancer chemotherapy

Chemotherapy kills tumor cells, but it also wreaks havoc on the rest of the body. A team of researchers led by Igor Roninson of the South Carolina College of Pharmacy just reported the discovery of a new class of drugs that reduces the adverse effects of cellular damage from chemotherapy.

8 Aug 2012

Clovis Oncology, Foundation Medicine enter diagnostic collaboration

Foundation Medicine, Inc. and Clovis Oncology, Inc. announced today that they have entered into a diagnostic collaboration.

6 Aug 2012

Scientists identify key factor that drives resistance to cancer drug

Developing resistance to chemotherapy is a nearly universal, ultimately lethal consequence for cancer patients with solid tumors - such as those of the breast, prostate, lung and colon - that have metastasized, or spread, throughout the body. A team of scientists led by Fred Hutchinson Cancer Research Center has discovered a key factor that drives this drug resistance - information that ultimately may be used to improve the effectiveness of therapy and buy precious time for patients with advanced cancer.

6 Aug 2012

Greenwich Hospital to educate women about breastfeeding during first week of August

At Greenwich Hospital, as throughout the world, the first week of August is recognized as World Breastfeeding Week to educate people about the health benefits of breastfeeding for both baby and mother. Promoted at the global level by the World Health Organization (WHO) and UNICEF, the spotlight is part of an effort to reduce world hunger and illness.

2 Aug 2012

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Vermillion, Inc., a leading molecular diagnostics company, today announced positive results from a new prospective, multi-center clinical study of its ovarian cancer diagnostic OVA1.

30 Jul 2012

Study investigates molecular markers in drug-resistant ovarian cancer

A new study by TCD researchers investigates drug-resistant ovarian cancer cells. The findings which have been recently published in the international publication, PLoS One will increase understanding of molecular markers in drug-resistant ovarian cancer with a view to improving clinical treatment.

27 Jul 2012

EntreMed commences ENMD-2076 Phase 2 study in triple-negative breast cancer

EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study.

25 Jul 2012

Pennsylvania Hospital to participate in Best Fed Beginnings

Pennsylvania Hospital (PAH) has been selected to participate in Best Fed Beginnings, a first-of-its-kind national effort to significantly improve breastfeeding rates in states where rates are currently the lowest.

25 Jul 2012

Cerulean commences dosing in CRLX101 Phase 2 study for ovarian cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.

23 Jul 2012

International Congress on Natural Products Research to be held in New York City

The urgent need to evaluate nature's repository of chemicals in plants, microbes, and marine organisms for their potential value in health care will be a major theme of a five-day scientific conference in New York that is expected to draw some 1,200 natural products researchers from around the world.

21 Jul 2012

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

The first patient has now been enrolled into the Phase 1 clinical trial sponsored by Viral Genetics' and supported by a donation from Scott and White Foundation. The trial will study Metabolic Disruption Technology (MDT) compounds in combination with an existing cancer therapy to treat drug-resistant ovarian cancer.

20 Jul 2012

ImmunoGen announces start of IMGN853 Phase I trial for ovarian cancer, other solid tumors

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN853 product candidate.

11 Jul 2012

New approach integrates rational drug design with supramolecular nanochemistry in cancer treatment

Researchers at Brigham and Women's Hospital (BWH) are the first to report a new approach that integrates rational drug design with supramolecular nanochemistry in cancer treatment.

11 Jul 2012

Methylation provides signal of unique mix of leukocytes

When a person is sick, there is a tell-tale sign in their blood: a different mix of the various types of immune cells called leukocytes. A group of scientists at several institutions including Brown University has discovered a way to determine that mix from the DNA in archival or fresh blood samples, potentially providing a practical new technology not only for medical research but also for clinical diagnosis and treatment monitoring of ailments including some cancers.

10 Jul 2012

ADCT, CRT sign agreements to develop ADCs against cancer

Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT) announce today that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT's 'warhead' and linker chemistries.

6 Jul 2012

PGD for breast cancer genes BRCA1/2 is now feasible

Preimplantation genetic diagnosis (PGD) for the breast cancer genes BRCA1/2 is now feasible and established, with good success rates for those treated, according to investigators from the reproduction, oncology and genetics centres of the university hospitals of Maastricht and Brussels.

3 Jul 2012